Not a traditional drug phase: Arterial Pulse Contour Analysis for Ventricular Dysfunction, Right
This single-center, prospective watch-and-measure (no experimental treatment required) study aims to evaluate whether dPmax, a measure of the maximum rate of arterial pressure rise obtained through pulse contour analysis, can predict right ventricular failure after left ventricular assist device (LVAD) implantation in adults. Measurements collected during routine monitoring before and after anesthesia induction will be analyzed alongside preoperative echocardiographic findings.
Official registry: https://clinicaltrials.gov/study/NCT07918690 · Pınar Kırdemir · enrollment listed as 89
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 89 people at Ankara. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Predictive Value of dPmax Measured by Pulse Contour Analysis for Postoperative Right Ventricular Failure in Patients Undergoing LVAD Implantation
Interventions: Arterial Pulse Contour Analysis
Primary outcome (registry wording): Right Ventricular Failure Within 30 Days After LVAD Implantation
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Age 18 years or older
- Scheduled for left ventricular assist device (LVAD) implantation
- Availability of the clinical data required for the study
Who the registry excludes
- Congenital heart disease associated with transposition of the great arteries
- Ongoing extracorporeal membrane oxygenation (ECMO) or extracorporeal ventricular assist device (ExVAD) support immediately before LVAD implantation
- Severe aortic regurgitation, severe peripheral arterial disease, or refractory and uncontrolled tachyarrhythmia that may interfere with arterial waveform analysis
Contact
No central phone on the registry card. Use the official listing to reach a site.
Sites listed on ClinicalTrials.gov
1 listed- Ankara Bilkent City Hospital — Ankara, Çankaya, Turkey (Türkiye) (recruiting)
FAQ about this NCT record
Is NCT07918690 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07918690?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07918690?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary